Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Change in Account Payables: 2023-2025

Historic Change in Account Payables for Immunocore Holdings (IMCR) over the last 3 years, with Sep 2025 value amounting to -$287,000.

  • Immunocore Holdings' Change in Account Payables rose 63.02% to -$287,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 60.92%. This contributed to the annual value of $7.3 million for FY2024, which is 177.03% up from last year.
  • As of Q3 2025, Immunocore Holdings' Change in Account Payables stood at -$287,000, which was up 95.86% from -$6.9 million recorded in Q2 2025.
  • Immunocore Holdings' Change in Account Payables' 5-year high stood at $6.0 million during Q2 2023, with a 5-year trough of -$6.9 million in Q2 2025.
  • Over the past 3 years, Immunocore Holdings' median Change in Account Payables value was -$287,000 (recorded in 2025), while the average stood at $547,545.
  • Data for Immunocore Holdings' Change in Account Payables shows a peak YoY increase of 244.05% (in 2025) and a maximum YoY decrease of 254.53% (in 2025) over the last 5 years.
  • Over the past 3 years, Immunocore Holdings' Change in Account Payables (Quarterly) stood at $3.8 million in 2023, then spiked by 56.70% to $5.9 million in 2024, then skyrocketed by 63.02% to -$287,000 in 2025.
  • Its last three reported values are -$287,000 in Q3 2025, -$6.9 million for Q2 2025, and $3.3 million during Q1 2025.